Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Physician-reported ECOG-PS versus patient-reported (self) ECOG-PS: Which one is a better predictor of survival in cancer?

View through CrossRef
The aim of this study is to determine the discrepancy and agreement between Eastern Cooperative Oncology Group Performance Status (ECOG-PS) scores evaluated by doctors and patients and examine the factors that influence the performance evaluation of doctors and patients. This study is a prospective and descriptive case-control study. General, demographic, and oncologic data of the patients were collected. e-control study. General, demographic, and oncologic data of the patients were collected. Patient-Reported Outcomes Measurement Information System (PROMIS) anxiety and depression surveys were conducted to determine patients' levels of anxiety and depression, and at the same time, both the doctors and the patients were asked to determine their performance status. As a result, the discrepancy in performance evaluation between the patient and the doctor, the factors affecting this discrepancy, and its effect on progression and survival were examined. 277 patients were included. 146 (52.7%) were male, and 131 (47.3%) were female. The most common cancers were breast cancer (17.7%, n=49) and lung cancer (17.3%, n=48). It was found that the doctors' assessment of patient performance increased the progression risk by 3.1 times (HR: 3.080, 95% CI: 1,671-5,675) in ECOG-PS 2 compared to ECOG-PS 0 and by 5 times (HR: 4.980, 95% CI 1.405-17.646) in ECOG-PS 3 compared to ECOG-PS 0. Our study determined a weak agreement between the doctor and patient in terms of performance assessment. The most significant reason for this discrepancy was found to be due to the levels of depression or anxiety in patients. In conclusion, it was demonstrated that the performance evaluations determined by doctors are more accurate and meaningful in terms of progression and survival results compared to those determined by patients.
Title: Physician-reported ECOG-PS versus patient-reported (self) ECOG-PS: Which one is a better predictor of survival in cancer?
Description:
The aim of this study is to determine the discrepancy and agreement between Eastern Cooperative Oncology Group Performance Status (ECOG-PS) scores evaluated by doctors and patients and examine the factors that influence the performance evaluation of doctors and patients.
This study is a prospective and descriptive case-control study.
General, demographic, and oncologic data of the patients were collected.
e-control study.
General, demographic, and oncologic data of the patients were collected.
Patient-Reported Outcomes Measurement Information System (PROMIS) anxiety and depression surveys were conducted to determine patients' levels of anxiety and depression, and at the same time, both the doctors and the patients were asked to determine their performance status.
As a result, the discrepancy in performance evaluation between the patient and the doctor, the factors affecting this discrepancy, and its effect on progression and survival were examined.
277 patients were included.
146 (52.
7%) were male, and 131 (47.
3%) were female.
The most common cancers were breast cancer (17.
7%, n=49) and lung cancer (17.
3%, n=48).
It was found that the doctors' assessment of patient performance increased the progression risk by 3.
1 times (HR: 3.
080, 95% CI: 1,671-5,675) in ECOG-PS 2 compared to ECOG-PS 0 and by 5 times (HR: 4.
980, 95% CI 1.
405-17.
646) in ECOG-PS 3 compared to ECOG-PS 0.
Our study determined a weak agreement between the doctor and patient in terms of performance assessment.
The most significant reason for this discrepancy was found to be due to the levels of depression or anxiety in patients.
In conclusion, it was demonstrated that the performance evaluations determined by doctors are more accurate and meaningful in terms of progression and survival results compared to those determined by patients.

Related Results

Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract Introduction Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
Autonomy on Trial
Autonomy on Trial
Photo by CHUTTERSNAP on Unsplash Abstract This paper critically examines how US bioethics and health law conceptualize patient autonomy, contrasting the rights-based, individualist...
Pembrolizumab and Sarcoma: A meta-analysis
Pembrolizumab and Sarcoma: A meta-analysis
Abstract Introduction: Pembrolizumab is a monoclonal antibody that promotes antitumor immunity. This study presents a systematic review and meta-analysis of the efficacy and safety...
Is a Fitbit a Diary? Self-Tracking and Autobiography
Is a Fitbit a Diary? Self-Tracking and Autobiography
Data becomes something of a mirror in which people see themselves reflected. (Sorapure 270)In a 2014 essay for The New Yorker, the humourist David Sedaris recounts an obsession spu...
International Breast Cancer Study Group (IBCSG)
International Breast Cancer Study Group (IBCSG)
This section provides current contact details and a summary of recent or ongoing clinical trials being coordinated by International Breast Cancer Study Group (IBCSG). Clinical tria...
Blogging Illness: Recovering in Public
Blogging Illness: Recovering in Public
As a mode of open access public self-expression, blogs are one form of the unfolding massification of culture (Lovink). Though widely varied in content and style, they are characte...
Are Cervical Ribs Indicators of Childhood Cancer? A Narrative Review
Are Cervical Ribs Indicators of Childhood Cancer? A Narrative Review
Abstract A cervical rib (CR), also known as a supernumerary or extra rib, is an additional rib that forms above the first rib, resulting from the overgrowth of the transverse proce...
Edoxaban and Cancer-Associated Venous Thromboembolism: A Meta-analysis of Clinical Trials
Edoxaban and Cancer-Associated Venous Thromboembolism: A Meta-analysis of Clinical Trials
Abstract Introduction Cancer patients face a venous thromboembolism (VTE) risk that is up to 50 times higher compared to individuals without cancer. In 2010, direct oral anticoagul...

Back to Top